Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning

In newly diagnosed aggressive non-Hodgkin lymphoma (NHL), a positive midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography (PET) scan often carries a poor prognosis, with reported 2-year event-free survival (EFS) rates of 0% to 30% after standard therapy. To determine the outcome...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kasamon, Yvette L., Wahl, Richard L., Ziessman, Harvey A., Blackford, Amanda L., Goodman, Steven N., Fidyk, Caroline A., Rogers, Kathryn M., Bolaños-Meade, Javier, Borowitz, Michael J., Ambinder, Richard F., Jones, Richard J., Swinnen, Lode J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4020440/
https://ncbi.nlm.nih.gov/pubmed/19167684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2008.11.026
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados